Literature DB >> 8094613

The conservative substitution Asp-645-->Glu in lysosomal alpha-glucosidase affects transport and phosphorylation of the enzyme in an adult patient with glycogen-storage disease type II.

M M Hermans1, E de Graaff, M A Kroos, H A Wisselaar, R Willemsen, B A Oostra, A J Reuser.   

Abstract

Glycogen-storage disease type II (GSDII) is caused by the deficiency of lysosomal alpha-glucosidase (acid maltase). This paper reports on the analysis of the mutant alleles in an American black patient with an adult form of GSDII (GM1935). The lysosomal alpha-glucosidase precursor of this patient has abnormal molecular features: (i) the molecular mass is decreased, (ii) the phosphorylation is deficient and (iii) the proteolytic processing is impaired. Sequence analysis revealed four mutations leading to amino acid alterations: Asp-645-->Glu, Val-816-->Ile, Arg-854-->Stop and Thr-927-->Ile. By using allele-specific oligonucleotide hybridization on PCR-amplified cDNA we have demonstrated that the Arg-854-->Stop mutation is located in one allele that is not expressed, and that the other allele contains the remaining three mutations. Each of the mutations was introduced in wild-type cDNA and expressed in COS cells to analyse the effect on biosynthesis, transport and phosphorylation of lysosomal alpha-glucosidase. The Val-816-->Ile substitution appeared to have no significant effect in contrast with results [Martiniuk, Mehler, Bodkin, Tzall, Hirshhorn, Zhong and Hirschhorn (1991) DNA Cell Biol. 10, 681-687] and was therefore defined as a polymorphism. The Thr-927-->Ile substitution deleting one of the seven glycosylation sites was found to be responsible for the decrease in molecular-mass, but not for the deficient proteolytic processing and phosphorylation. It did not cause the enzyme deficiency either. The third mutation leading to the Asp-645-->Glu substitution was proven to account in full for the observed defects in transport, phosphorylation and proteolytic processing of the newly synthesized alpha-glucosidase precursor of the patient.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8094613      PMCID: PMC1132230          DOI: 10.1042/bj2890687

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  28 in total

1.  Characterization of the molecular defect in infantile and adult acid alpha-glucosidase deficiency fibroblasts.

Authors:  N G Beratis; G U LaBadie; K Hirschhorn
Journal:  J Clin Invest       Date:  1978-12       Impact factor: 14.808

2.  Biosynthesis and intracellular transport of alpha-glucosidase and cathepsin D in normal and mutant human fibroblasts.

Authors:  R P Oude Elferink; J Van Doorn-Van Wakeren; A Strijland; A J Reuser; J M Tager
Journal:  Eur J Biochem       Date:  1985-11-15

3.  Adult forms of glycogenosis type II. A defect in an early stage of acid alpha-glucosidase realization.

Authors:  A J Reuser; M Kroos
Journal:  FEBS Lett       Date:  1982-09-20       Impact factor: 4.124

4.  Biosynthesis of lysosomal enzymes in fibroblasts. Synthesis as precursors of higher molecular weight.

Authors:  A Hasilik; E F Neufeld
Journal:  J Biol Chem       Date:  1980-05-25       Impact factor: 5.157

5.  Biochemical, immunological, and cell genetic studies in glycogenosis type II.

Authors:  A J Reuser; J F Koster; A Hoogeveen; H Galjaard
Journal:  Am J Hum Genet       Date:  1978-03       Impact factor: 11.025

6.  Isolation of a cDNA for human acid alpha-glucosidase and detection of genetic heterogeneity for mRNA in three alpha-glucosidase-deficient patients.

Authors:  F Martiniuk; M Mehler; A Pellicer; S Tzall; G La Badie; C Hobart; A Ellenbogen; R Hirschhorn
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

7.  alpha-Glucosidase deficiency in generalized glycogenstorage disease (Pompe's disease).

Authors:  H G HERS
Journal:  Biochem J       Date:  1963-01       Impact factor: 3.857

8.  Defects in synthesis, phosphorylation, and maturation of acid alpha-glucosidase in glycogenosis type II.

Authors:  A J Reuser; M Kroos; R P Oude Elferink; J M Tager
Journal:  J Biol Chem       Date:  1985-07-15       Impact factor: 5.157

9.  Genetic heterogeneity in acid alpha-glucosidase deficiency.

Authors:  N G Beratis; G U LaBadie; K Hirschhorn
Journal:  Am J Hum Genet       Date:  1983-01       Impact factor: 11.025

10.  The use of synthetic oligonucleotides as hybridization probes. II. Hybridization of oligonucleotides of mixed sequence to rabbit beta-globin DNA.

Authors:  R B Wallace; M J Johnson; T Hirose; T Miyake; E H Kawashima; K Itakura
Journal:  Nucleic Acids Res       Date:  1981-02-25       Impact factor: 16.971

View more
  13 in total

1.  Atypical immunologic response in a patient with CRIM-negative Pompe disease.

Authors:  Mary-Alice Abbott; Sean N Prater; Suhrad G Banugaria; Susan M Richards; Sarah P Young; Amy S Rosenberg; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2011-08-11       Impact factor: 4.797

2.  Functional analysis of variant lysosomal acid glycosidases of Anderson-Fabry and Pompe disease in a human embryonic kidney epithelial cell line (HEK 293 T).

Authors:  Hatim Y Ebrahim; Robert J Baker; Atul B Mehta; Derralynn A Hughes
Journal:  J Inherit Metab Dis       Date:  2011-10-05       Impact factor: 4.982

3.  Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience.

Authors:  Deeksha S Bali; Jennifer L Goldstein; Suhrad Banugaria; Jian Dai; Joanne Mackey; Catherine Rehder; Priya S Kishnani
Journal:  Am J Med Genet C Semin Med Genet       Date:  2012-01-17       Impact factor: 3.908

4.  Disease-causing mutations in exon 11 of the medium-chain acyl-CoA dehydrogenase gene.

Authors:  B S Andresen; T G Jensen; P Bross; I Knudsen; V Winter; S Kølvraa; L Bolund; J H Ding; Y T Chen; J L Van Hove
Journal:  Am J Hum Genet       Date:  1994-06       Impact factor: 11.025

5.  Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II.

Authors:  C F Boerkoel; R Exelbert; C Nicastri; R C Nichols; F W Miller; P H Plotz; N Raben
Journal:  Am J Hum Genet       Date:  1995-04       Impact factor: 11.025

6.  Acid alpha-glucosidase deficiency: identification and expression of a missense mutation (S529V) in a Japanese adult phenotype.

Authors:  H Tsunoda; T Ohshima; J Tohyama; M Sasaki; N Sakuragawa; F Martiniuk
Journal:  Hum Genet       Date:  1996-04       Impact factor: 4.132

7.  Variable clinical features and genotype-phenotype correlations in 18 patients with late-onset Pompe disease.

Authors:  Jousef Alandy-Dy; Marie Wencel; Kathy Hall; Julie Simon; Yanjun Chen; Erik Valenti; Jade Yang; Deeksha Bali; Anita Lakatos; Namita Goyal; Tahseen Mozaffar; Virginia Kimonis
Journal:  Ann Transl Med       Date:  2019-07

8.  Ultrastructural analysis of development of myocardium in calreticulin-deficient mice.

Authors:  Mira D Lozyk; Sylvia Papp; Xiaochu Zhang; Kimitoshi Nakamura; Marek Michalak; Michal Opas
Journal:  BMC Dev Biol       Date:  2006-11-19       Impact factor: 1.978

9.  Clinical Laboratory Experience of Blood CRIM Testing in Infantile Pompe Disease.

Authors:  Deeksha S Bali; Jennifer L Goldstein; Catherine Rehder; Zoheb B Kazi; Kathryn L Berrier; Jian Dai; Priya S Kishnani
Journal:  Mol Genet Metab Rep       Date:  2015-12-01

10.  GNAI3: Another Candidate Gene to Screen in Persons with Ocular Albinism.

Authors:  Alejandra Young; Uma Dandekar; Calvin Pan; Avery Sader; Jie J Zheng; Richard A Lewis; Debora B Farber
Journal:  PLoS One       Date:  2016-09-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.